AZNAstraZenecaRunning, no new patients
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 114 (final count)
- Started
- Aug 5, 2025
- Main results expected
- Nov 30, 2026
- Fully finished
- Dec 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS) per RECIST 1.1
Measured over: From the date of first dose until the date of objective PD per RECIST 1.1 or death, whichever came first. It will be assessed when approximately 69 PFS events have occurred (60% maturity), approximately 8 months after the last patients dosed.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07081633 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC